SPY424.31+0.70 0.17%
DIA345.12+0.14 0.04%
IXIC14,069.42+49.09 0.35%

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $170

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $175 to $170.

05/11/2021 06:35
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $175 to $170.